Business
Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like MPS II moving into the spotlight.
FEATURED STORIES
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
“These kinds of situations remind people how important diagnostics are,” Hawkins told BioSpace in an interview.
Based in New York City, Redpin has a proprietary chemogenetics platform for targeted cell therapies.
Kallyope Chief Executive Officer Nancy Thornberry said the company’s journey to becoming a “first-mover in the gut-brain axis space” is coming to fruition.
Rocket Pharmaceuticals CEO Gaurav Shah said the remote-working policies that have resulted from the global COVID-19 pandemic have created a challenging time for the pharmaceutical industry, as well as the rest of the global community, but believes a silver lining will be forthcoming.
To combat the growing number of cases, the state is pulling out the stops in testing the use of antibodies from the plasma of recovered COVID-19 patients.
“The industry is increasing capacities, but at the same time infection rates are even increasing faster,” said Roche CEO Severin Schwan. “At the moment, capacities are limited. That is why we have to prioritize testing to higher risk patients.”
Organizations should plan for the worst and hope for the best, ensuring critical research can be continued without risking the safety of employees or the continuity of the company.
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
Under terms of the agreement, Astellas will make an upfront cash payment of $80 million to CytomX.
Europe’s new pharmaceutical roadmap is designed to reinvigorate innovation in the pharmaceutical industry to make it competitive with the United States.